Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.

Related Keywords

,Myelodysplastic Syndromes ,Recent Updates ,Evolving Treatment Paradigms ,Data From ,Mds ,Myelodysplastic Syndromes Recent Updates ,Treatment Evolution Myelodysplastic Syndromes ,Mds Management ,Pasco ,Asco 2023 ,2023 Asco Annual Meeting ,American Society Of Clinical Oncology ,Prognosis ,Mds Symptoms ,Mds Diagnosis ,Mds Presentations ,High Risk Mds ,Low Risk Mds ,